UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
of
the Securities Exchange Act of 1934
For the
month of March, 2009
Commission
File Number: 000-51310
XTL Biopharmaceuticals
Ltd.
(Translation
of registrant's name into English)
711
Executive Blvd., Suite Q
Valley Cottage, New York
10989
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F.
Form
20-F x Form
40-F o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7): ____
Indicate
by check mark whether by furnishing the information contained in this Form, the
registrant is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes o No
x
If “Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82- N/A
Incorporation
by Reference: This Form 6-K of XTL Biopharmaceuticals Ltd. dated March 11, 2009
is hereby incorporated by reference into the registration statements on Form F-3
(File No. 333-141529, File No. 333-147024 and File No. 333-153055) filed by XTL
Biopharmaceuticals Ltd. with the Securities and Exchange Commission on March 23,
2007 , October 30, 2007 and August 15, 2008, respectively, and the registration
statements on Form S-8 (File No. 333-148085, File No. 333-148754 and File No.
333-154795) filed by XTL Biopharmaceuticals Ltd. with the Securities and
Exchange Commission on December 14, 2007, January 18, 2008, and October 28,
2008, respectively.
XTL
Biopharmaceuticals Ltd. Extraordinary General Meetings Postponed Until March 18,
2009
Valley Cottage, New York, March 11,
2009 - XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB; TASE: XTL) announced
today that its Extraordinary General Meetings (“EGMs”) were postponed for one
week in accordance with its articles of association due to the absence of a
quorum. The postponed EGMs will take place at the Company, Building 3, Kiryat
Weizmann Science Park, Rehovot, Israel 76100 at 3:00 p.m. and 5:30 p.m. Israel
time on March 18, 2009.
Any proxy
votes received at any time up to 48 hours prior to the postponed EGM will be
included in the total votes counted for the EGMs. Those shareholders who have a
valid “proof of ownership” in Israel or a letter of representation from
Computershare, the Company’s UK registrars, or a letter of representation from
the Bank of NY for an ADR owner, and attend the meeting in person will also be
permitted to vote.
Contact:
Ron
Bentsur, Co-Chief Executive Officer
Tel:
+1-(845)-267-0707 ext. 224
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
|
|
XTL
BIOPHARMACEUTICALS LTD.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Date:
March 11, 2009
|
By:
|
/s/ Ron Bentsur
|
|
|
|
Ron
Bentsur
|
|
|
|
Chief
Executive Officer
|